Taysha Gene Therapies, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Taysha Gene Therapies, Inc. (TSHA) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 38.17 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-16.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-16
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 38.17M shares, a 3.20% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 38.12M shares, a 2.65% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 38.00M shares, a 223.90% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 37.48M shares, a 244.00% increase year-over-year.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 37.65M shares, a 113.13% increase from fiscal 2020.
- Taysha Gene Therapies, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 17.67M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 0 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2022-03-31 | 38.17M shares 10-Q · filed 2022-05-16 | 38.15M shares derived: average of 2 quarters · filed 2022-05-16 | 38.10M shares derived: average of 3 quarters · filed 2022-05-16 | 37.94M shares derived: average of 4 quarters · filed 2022-05-16 | |
| 2021-12-31 | 38.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 38.06M shares derived: average of 2 quarters · filed 2022-03-31 | 37.87M shares derived: average of 3 quarters · filed 2022-03-31 | 37.65M shares 10-K · filed 2022-03-31 | |
| 2021-09-30 | 38.00M shares 10-Q · filed 2021-11-10 | 37.74M shares derived: average of 2 quarters · filed 2021-11-10 | 37.50M shares 10-Q · filed 2021-11-10 | 37.40M shares derived: average of 4 quarters · filed 2022-05-16 | |
| 2021-06-30 | 37.48M shares 10-Q · filed 2021-08-16 | 37.24M shares 10-Q · filed 2021-08-16 | 37.20M shares derived: average of 3 quarters · filed 2022-05-16 | 30.83M shares derived: average of 4 quarters · filed 2022-05-16 | |
| 2021-03-31 | 36.99M shares 10-Q · filed 2022-05-16 | 37.06M shares derived: average of 2 quarters · filed 2022-05-16 | 28.62M shares derived: average of 3 quarters · filed 2022-05-16 | 24.19M shares derived: average of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | 37.13M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | 24.43M shares derived: average of 2 quarters · filed 2022-03-31 | 19.92M shares derived: average of 3 quarters · filed 2022-03-31 | 17.67M shares 10-K · filed 2022-03-31 | |
| 2020-09-30 | 11.73M shares 10-Q · filed 2021-11-10 | 11.31M shares derived: average of 2 quarters · filed 2021-11-10 | 11.18M shares 10-Q · filed 2021-11-10 | 10.79M shares derived: average of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | 10.89M shares 10-Q · filed 2021-08-16 | 10.89M shares 10-Q · filed 2021-08-16 | 10.47M shares derived: average of 3 quarters · filed 2021-08-16 | ||
| 2020-03-31 | 10.89M shares 10-Q · filed 2021-05-11 | 10.26M shares derived: average of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | 9.63M shares 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | 8.72M shares 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |